Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (February 2020)
18 slides from Arbutus Biopharma's investor presentation, Feb 10, 2020
Slide 1: Singularly Focused on HBV
Singularly Focused on HBV February 2020 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this pur
Slide 3: HBV Presents a Significant Unmet Medical Need
HBV Presents a Significant Unmet Medical Need 15M >257Mpeople are chronically Europe infected with HBV, globally. 2M United States 90M China ~900k people die every year as a consequence despite the availability of effective vaccines and antivirals. NASDAQ: ABUS www.arbutusbio.com Sources: Global Hep
Slide 4: Significant Opportunity to Improve Standard of Care Therapies for Chronic HBV
Significant Opportunity STANDARD OF CARE THERAPIES FOR CHRONIC HBV to Improve New HBV HBV Cure PegIFN Entecavir Tenofovir Therapies rate of Dosing Duration 48-weeks Chronic Chronic Rates Undetectable HBV DNA + HBV DNA rate of Undetectable 7-19% 67-90% 76-93% HBV cures are achievable with (<60-80 IU/
Slide 5: Compelling Growth Opportunity in the HBV Market
Compelling Growth Opportunity in the HBV Market 257M chronic HBV 10.5% Diagnosed An HBV curative regimen 27M would substantially increase diagnosis and treatmenttreatment 1.8% Treated rates to unlock significant market growth opportunities. 4.5M Low due to sub- optimal SOC cure rate and asymptomatic
Slide 6: Investment Highlights
Investment Highlights Singular therapeutic focus - curing chronic Hepatitis B Virus (HBV) Infection Team With Significant Goal of Broad Strong Antiviral Unmet Medical Functional HBV Financial Expertise & Need in HBV Cure Portfolio Position Proven Track Record Global HBV prevalence Undetectable HBV D
Slide 7: Proven Leadership Team
Proven Leadership Team William H. Collier Michael J. Sofia, PhD Gaston Picchio, PhD Successful track records President and CEO Chief Scientific Officer Chief Development Officer in the discovery, development, and commercialization of multiple antivirals including sofosbuvir, etravirine, rilpivirine,
Slide 8: HBV Lifecycle Illustrates Key Points for Intervention
HBV Lifecycle Illustrates Key Points for Intervention A combination of agents with complementary MOA is needed to cure HBV 1 –Nucleoside Analogue 2 –Capsid Inhibitor 3 –RNAi & RNA Destabilizer 2 3 1 2 NASDAQ: ABUS www.arbutusbio.com
Slide 9: Keys to Therapeutic Success
1 Reduce/Suppress 2 Reduce/Suppress Keys to Viral DNA Viral Antigens Therapeutic Block Replication Block HBsAg . NA . RNAi . Capsid Inhibitor . RNA Destabilizer Success . RNAi . RNA Destabilizer Reduce cccDNA Pool . Capsid Inhibitor Suppress HBV DNA and viral antigens Leading to an Reawaken host HBV
Slide 10: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Lead IND Enabling Healthy Subjects HBV Subjects Phase II Optimization HBsAg Reduction RNAi AB-729 HBV RNA Destabilizers Next Gen HBV DNA Suppression Capsid Inhibitor AB-836 Immune Reawakening PD-L1 1st gen NASDAQ: ABUS www.arbutusbio.com 10
Slide 11: AB-729 RNAi Therapeutic
AB-729 RNAi Single trigger RNAi agent targeting all HBV transcripts Therapeutic Inhibits HBV replication and lowers all HBV antigens Pan-genotypic activity across HBV genotypes Duration of HBsAg reduction supports once per month dosing Proprietary GalNAc-conjugate delivery technology provides Demons
Slide 12: AB-729 Single Dose Response
AB-729 Single Dose Response 4 AB-729 Saline 3 1 mg/kg In Vivo Single & 3 mg/kg 2 9 mg/kg Multiple Dose 1 (LOG IU/mL)(LOG Serum HBsAg Response & 0 SC dose LLOQ Duration -1 0 2 4 6 8 10 Study Week Strong dose response 5 in AAV mouse model AB-729 Multiple Dose Response Stepwise reduction of HBsAg 4 Sal
Slide 13: AB-729 Phase 1a/b Study Design
AB-729 Phase 1a/b Part 1: Part 2: Part 3: Study Design Blinded SAD in SAD in HBV Subjects 3 and 6 Month Multiple- Healthy Volunteers dose in HBV Subjects Starting dose 60 mg Starting dose selected Dose selected from part 2 Preliminary results from Part 1 anticipated late Q1 2020 6 subjects per cohor
Slide 14: AB-452 and Next Gen RNA Destabilizer Program
AB-452 and Next Gen RNA Destabilizer Program . AB-452 development discontinued following extensive pre-clinical evaluations . However, we believe this target offers potential for an oral HBsAg reducing agent and potential all oral combination therapy . Continuing active research and development of a
Slide 15: AB-836 Capsid Inhibitor
AB-836 Capsid . Novel chemical series differentiated from AB-506 and other competitor Inhibitor compounds in the Class II capsid inhibitor space . Leverages a novel binding site within the core protein dimer-dimer interface IND enabling . Improved intrinsic potency with EC50 < 10 nM studies ongoing
Slide 16: AB-836: A Next Generation Capsid Inhibitor
AB-836: A Next Generation Capsid Inhibitor cccDNA Formation / Human Serum HBV DNA / 1o Mechanism 2o Mechanism Shift HBV infected HBV infected Core I105T HBV infected HepDE19 (FC in EC in 40% Compound PHH HepG2-NTCP-C4 Mutation HepG2-NTCP-C4 50 (EC50 μM) Human Serum) (EC50 μM) (EC50 μM) (EC50 µM) (HB
Slide 17: Key Objectives for 2020
Key Objectives for 2020 Objective Anticipated Timing AB-729 preliminary phase 1a/1b single dose data Late 1Q 2020 AB-729 multiple dose data 2H 2020 AB-836 complete IND enabling studies 2H 2020 NASDAQ: ABUS www.arbutusbio.com 17
Slide 18: Investment Highlights
Investment Highlights Singular therapeutic focus - curing chronic Hepatitis B Virus (HBV) Infection Team With Significant Goal of Broad Strong Antiviral Unmet Medical Functional HBV Financial Expertise & Need in HBV Cure Portfolio Position Proven Track Record Global HBV prevalence Delivered through
Arbutus Biopharma — Investor Presentation (February 2020) on 6ix